Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 19/20 | 0.84 |
| ▸ | CDK4 | P11802 | 14/20 | 0.84 |
| ▸ | CDK6 | Q00534 | 9/20 | 0.80 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | CCND3 | P30281 | 1/20 | 0.59 |
| ▸ | CDK7 | P50613 | 1/20 | 0.59 |
| ▸ | CCNH | P51946 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514918 | 1.00 | CCND1 (0.84) | CCND1CDK4CDK6CCNA2CDK2 | |
| SCHEMBL25284787 | 0.93 | CCND1 (0.76) | CCND1CDK4CDK6CCNA2CDK2 | |
| SCHEMBL29514856 | 0.93 | CCND1 (0.76) | CCND1CDK4CDK6CCNA2CDK2 | |
| SCHEMBL29515005 | 0.91 | CCND1 (1.00) | CCND1CDK4CDK6CCNA2CDK2 | |
| SCHEMBL24323622 | 0.91 | CCND1 (0.84) | CCND1CDK4CDK6CCNA2CDK2 | |
| SCHEMBL24322348 | 0.91 | CCND1 (0.84) | CCND1CDK4CDK6 | |
| SCHEMBL29514967 | 0.89 | CCND1 (1.00) | CCND1CDK4CDK6CCNA2CDK2 | |
| SCHEMBL24322192 | 0.89 | CCND1 (1.00) | CCND1CDK4CDK6CCNA2CDK2 | |
| SCHEMBL25284830 | 0.89 | CCND1 (1.00) | CCND1CDK4CDK6CCNA2CDK2 | |
| SCHEMBL29515035 | 0.89 | CCND1 (1.00) | CCND1CDK4CDK6CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | claimed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | claimed |
| US-20220089608-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2022-03-24 | — | — | US | claimed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220089608-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089608-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CCND1 46/4885CDK4 12/4885CDK6 1/4885 |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CCND1 46/4885CDK4 12/4885CDK6 1/4885 |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | CCND1 46/4885CDK4 12/4885CDK6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.